Successful quarter for Diamyd

Elisabeth Lindner, President and CEO of Diamyd Medical, communicates in the CEO overview in the quarterly report published today, that the last quarter has been both successful and of vital importance to the development of the company.

Phase III studies have been approved and initiated in Sweden and the US, and approvals are expected from a number of European countries in August and September. Inclusion of patients is ongoing in Sweden and ethics approvals for participating US sites have started to come in.

A successful direct placement was accomplished and warrants have been listed for trading.

To date, all pursued and planned clinical trials with Diamyd® concern patients diagnosed with type 1 diabetes or LADA. The Chairman of TrialNet, Professor Jay Skyler, communicated during the ADA conference in San Fransisco on 9th of June, that in addition to the planned intervention study with 126 patients, a prevention study with Diamyd® in healthy individuals at risk to develop type 1 diabetes is planned.

- Diamyd Medical has experienced a fantastic quarter, says President and CEO Elisabeth Lindner. We have, as a fairly small research company, in a very short period of time, succeeded to move our Phase III studies into a phase where we are actively including patients. Furthermore, there is interest from TrialNet to study whether Diamyd® can prevent type 1 diabetes. Should Diamyd® not only improve the situation for children, that already have diabetes, but also prevent the disease, this would be a dramatic break-through. Finally, our financial position is strengthened after a fully subscribed direct issue of new shares. It is with great pleasure that I am publishing this quarterly report, concludes President and CEO Elisabeth Lindner.